Norcantharidin, an effective IL-6 inhibitor, enhances the antitumor activity of sorafenib in a rat model of hepatocellular carcinoma through the IL-6–STAT3 pathway[32]. This evidence concerns the gene STAT3 and hepatocellular carcinoma.